Tuesday, July 21, 2020 7:39:27 AM
Exactly what would you have had him do differently? put differently, given the identical circumstances with FDA,
if you had been head of the company all this time, what would your strategy have been? What would you have done differently?
What FDA circumstances are we referring to? What did the FDA do wrong? It was Nasrat who wasted millions of dollars and multiple years on Zombie SequestOx, despite knowing from the start it was not bioequivalent. (And despite what he told investors in a PR). FDA had nothing to do with the time & money wasted on the applesauce escapades. FDA did not screw up the reformulated bead, after another year and a few million dollars more. Nasrat did have a great idea of calling on an expert formulator to get the third attempt correct. Too bad he didn't have that idea 5 years and 500 million shares sooner. That bead now sits collecting dust, except for the lawyers fees going toward Nasrat's vanity patent application.
It was bad policy from the FDA that caused the demise of the 2-bead ADF versions of Norco and Percocet, but I gave Nasrat great credit for recovering those expenses by filing ANDA's for generic Norco and Percocet. We spent substantial sums getting those drugs approved, along with our own ANDA for methadone, and before we could recover any of our investment, they got sold off for pennies on the dollar, along with our generic Dilaudid. These bread & butter ANDA's would be adding very nice revenue right now. Not one responsible manufacturer of generic opioids has been sued by anyone. What bullshit.
Nasrat may yet lead this company to the promised land, but please spare me the infallible savior complex. Jeebus, Nasrat somehow even manages to turn our successes into failures. I bought shares last year for 6.5 cents, same price I paid 6 years ago, except back then there were only 340 million outstanding shares and now there are 840 million. Looks like I'll have the same opportunity this week. So "FDA circumstances" had nothing to do with Nasrat wasting 500 million shares from the treasury with ZERO shareholder value to show for it.
Occam's razor: the simplest solution is most likely the right one.
Hanlon's razor: never attribute to malice that which is adequately explained by stupidity.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
